Description: Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.
Home Page: www.darebioscience.com
DARE Technical Analysis
3655 Nobel Drive
San Diego,
CA
92122
United States
Phone:
858 926 7655
Officers
| Name | Title |
|---|---|
| Ms. Sabrina Martucci Johnson | Pres, CEO, Sec. & Director |
| Ms. Lisa Walters-Hoffert | Chief Financial Officer |
| Mr. John A. Fair | Chief Strategy Officer |
| Mr. Mark Walters | VP of Operations |
| Ms. MarDee J. Haring-Layton | VP of Accounting & Fin. |
| Dr. David Friend | Chief Scientific Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Supplies |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8971 |
| Price-to-Sales TTM: | 7.6682 |
| IPO Date: | 2014-04-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 20 |